These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10305387)

  • 1. Did FDA jump the gun?
    Archambault GF
    Hosp Formul; 1977 Oct; 12(10):722. PubMed ID: 10305387
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA acts on estrogen, progestin labeling.
    FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006
    [No Abstract]   [Full Text] [Related]  

  • 3. Estrogen PPIs. An FDA survey.
    Morris LA; Myers A; Gibbs P; Lao C
    Am Pharm; 1980 Jun; NS20(6):22-6. PubMed ID: 7395715
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription drug products; patient labeling requirements: proposed rule.
    Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
    [No Abstract]   [Full Text] [Related]  

  • 5. Developing drug information for patients.
    Hecht A
    FDA Consum; 1977 Sep; 11(7):16-9. PubMed ID: 10304999
    [No Abstract]   [Full Text] [Related]  

  • 6. Informing patients about drugs: a wrong way and a right way.
    Woodson DW
    Med World News; 1979 Jun; 20(13):6. PubMed ID: 10242286
    [No Abstract]   [Full Text] [Related]  

  • 7. The status of unit-of-use in Europe and the United States: an evolution in drug dispensing.
    Archambault GF
    Hosp Formul; 1979 Jan; 14(1):70-1, 75-6, 78-9. PubMed ID: 10297341
    [No Abstract]   [Full Text] [Related]  

  • 8. Will PPIs affect your patients' attitudes?
    Patient Care; 1979 Feb; 13(3):190-1, 195-6. PubMed ID: 10240261
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient package inserts: the proper prescription?
    Rowe HM
    Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
    [No Abstract]   [Full Text] [Related]  

  • 10. Rx with a dose of info.
    Miller RW
    FDA Consum; 1980 Nov; 14(9):22-3. PubMed ID: 10309292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unapproved uses of approved drugs: The physician, the package insert, and the FDA.
    Pediatrics; 1978 Aug; 62(2):262-4. PubMed ID: 693165
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA puts forth proposal to mandate patient information.
    Wechsler J
    Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA and the practice of medicine.
    Ryan KJ
    N Engl J Med; 1977 Dec; 297(23):1287-8. PubMed ID: 917077
    [No Abstract]   [Full Text] [Related]  

  • 15. History of FDA patient package insert requirements.
    Am J Hosp Pharm; 1980 Dec; 37(12):1660-1. PubMed ID: 7004180
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA sends note to 36 million urging them to know more about medications.
    Am Coll Physicians Obs; 1983 Jun; 3(6):24-5. PubMed ID: 10261422
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA insists that oestrogen products for menopause carry a warning.
    Gottlieb S
    BMJ; 2003 Jan; 326(7381):126. PubMed ID: 12531839
    [No Abstract]   [Full Text] [Related]  

  • 18. Is the FDA packing a surprise for you?
    Chapman S
    Leg Aspects Med Pract; 1979 Nov; 7(11):35-8. PubMed ID: 263195
    [No Abstract]   [Full Text] [Related]  

  • 19. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA proposes that patient package insert program be rescinded.
    Hospitals; 1982 Feb; 56(4):84. PubMed ID: 7054117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.